Acquisition Opportunity DrugScan has a recent acquisition history and is part of a larger network under ACM Global Laboratories, suggesting potential cross-sell or integration opportunities for expanded toxicology, infectious disease testing, and program management services within a larger healthcare ecosystem.

National Reach With operations spanning 48 states and a national footprint, there is strong potential to offer scalable, compliant testing programs to multi-site employers, healthcare providers, and risk management firms seeking standardized workplace drug testing and infectious disease screening.

Compliance & Certification CAP and SAMHSA-certified laboratories highlight stringent quality and regulatory standards, which can be leveraged to pitch high-stakes clients (e.g., regulated industries, federal contractors) requiring robust QA, traceability, and HIPAA-compliant data handling.

Public Health Alignment Real-time PCR infectious disease testing (e.g., COVID-19) through ViraScan positions DrugScan to offer ongoing surveillance and diagnostic services to hospitals, schools, and large employers seeking rapid, reliable infectious disease programs.

Growth & Revenue Potential Revenue scale ($50M-$100M) and a mid-size employee base indicate opportunities to upsell enhanced program management, targeted drug monitoring, addiction monitoring, and workplace compliance services to existing and new enterprise clients in regulated industries.